Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CPT Code Anticipated For AMD Combination Therapy Using Lasers, QLT Says

This article was originally published in The Gray Sheet

Executive Summary

A combination drug/device therapy for "wet" age-related macular degeneration (AMD) will likely have a current procedural terminology (CPT) payment code in effect by Jan. 1. The treatment uses QLT PhotoTherapeutics' injectable drug Visudyne (verteporfin) activated by lasers manufactured by Coherent Medical (Opal Photoactivator) and Zeiss Humphrey Systems (Visulas 690).
Advertisement

Related Content

QLT PhotoTherapeutics
QLT PhotoTherapeutics
Advertisement
UsernamePublicRestriction

Register

MT013984

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel